首页> 美国卫生研究院文献>Diabetes Metabolic Syndrome and Obesity: Targets and Therapy >HbA1c for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications and how well does the 6.5 cutoff perform?
【2h】

HbA1c for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications and how well does the 6.5 cutoff perform?

机译:HbA1c用于诊断2型糖尿病。是否有一个最佳的切入点来评估糖尿病并发症的高风险?6.5%的切入点表现如何?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Glycated hemoglobin (HbA1c) has recently been recommended for the diagnosis of type 2 diabetes mellitus (T2DM) by leading diabetes organizations and by the World Health Organization. The most important reason to define T2DM is to identify subjects with high risk of diabetes complications who may benefit from treatment. This review addresses two questions: 1) to assess from existing studies whether there is an optimal HbA1c threshold to predict diabetes complications and 2) to assess how well the recommended 6.5% cutoff of HbA1c predicts diabetes complications. HbA1c cutoffs derived from predominantly cross-sectional studies on retinopathy differ widely from 5.2%–7.8%, and among other reasons, this is due to the heterogeneity of statistical methods and differences in the definition of retinopathy. From the few studies on other microvascular complications, HbA1c thresholds could not be identified. HbA1c cutoffs make less sense for the prediction of cardiovascular events (CVEs) because CVE risks depend on various strong risk factors (eg, hypertension, smoking); subjects with low HbA1c levels but high values of CVE risk factors were shown to be at higher CVE risk than subjects with high HbA1c levels and low values of CVE risk factors. However, the recommended 6.5% threshold distinguishes well between subjects with and subjects without retinopathy, and this distinction is particularly strong in severe retinopathy. Thus, in existing studies, the prevalence of any retinopathy was 2.5 to 4.5 times as high in persons with HbA1c-defined T2DM as in subjects with HbA1c <6.5%. To conclude, from existing studies, a consistent optimal HbA1c threshold for diabetes complications cannot be derived, and the recommended 6.5% threshold has mainly been brought about by convention rather than by having a consistent empirical basis. Nevertheless, the 6.5% threshold is suitable to detect subjects with prevalent retinopathy, which is the most diabetes specific complication. However, most of the studies on associations between HbA1c and microvascular diabetes complications are cross-sectional, and there is a need for longitudinal studies.
机译:领先的糖尿病组织和世界卫生组织最近推荐使用糖化血红蛋白(HbA1c)诊断2型糖尿病(T2DM)。定义T2DM的最重要原因是确定患有糖尿病并发症的高风险患者,这些患者可能会从治疗中受益。这项审查解决了两个问题:1)从现有研究中评估是否存在最佳的HbA1c阈值来预测糖尿病并发症; 2)评估建议的6.5%HbA1c临界值预测糖尿病并发症的程度。 HbA1c临界值主要来自于视网膜病变的横断面研究,差异在5.2%–7.8%之间,差异很大,此外,这还归因于统计方法的异质性和视网膜病变定义的差异。从对其他微血管并发症的少数研究中,无法确定HbA1c阈值。 HbA1c临界值对于心血管事件(CVE)的预测意义不大,因为CVE风险取决于各种强大的风险因素(例如,高血压,吸烟)。 HbA1c水平低但CVE危险因素值高的受试者被证明比HbA1c水平高和CVE危险因素值低的受试者具有更高的CVE风险。但是,推荐的6.5%阈值在患有视网膜病的受试者和未患有视网膜病的受试者之间有很好的区分,并且这种区分在严重的视网膜病中尤为明显。因此,在现有研究中,HbA1c定义的T2DM患者的任何视网膜病变的患病率是HbA1c <6.5%的患者的2.5至4.5倍。总之,从现有研究得出的结论是,不能得出一致的最佳糖尿病并发症HbA1c阈值,推荐的6.5%阈值主要是由惯例带来的,而不是具有一致的经验基础。尽管如此,6.5%的阈值仍适合检测患有普遍性视网膜病变的受试者,这是糖尿病最常见的并发症。然而,关于HbA1c与微血管糖尿病并发症之间关系的大多数研究都是横断面的,因此需要进行纵向研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号